Zura Bio to Deliver Presentation at the Jefferies International Healthcare Symposium
**Zura Bio to Present at Jefferies Global Healthcare Conference 2025**
Zura Bio Limited, a clinical-stage, multi-asset immunology company, is set to present a corporate overview at the Jefferies Global Healthcare Conference on June 4, 2025. The conference, scheduled from June 3 to June 5 in New York, NY, will also feature presentations from companies such as Codexis and GRAIL.
The presentation by Zura Bio will take place at 3:10 PM ET. The company's lead product candidate, tibulizumab (ZB-106), is currently being evaluated in two separate Phase 2 clinical studies. The presentation is expected to provide insights into the progress of these studies and the potential of tibulizumab.
Zura Bio's pipeline also includes dual-pathway product candidates designed to target key mechanisms of immune system imbalance. Other product candidates, crebankitug (ZB-168) and torudokimab (ZB-880), have completed Phase 1/1b studies.
A live webcast of the presentation will be available on the News & Events page in the Investors section of the Zura Bio website. Following the event, a replay of the presentation will be accessible and will remain archived on the website for at least 30 days.
For more information about Zura Bio's presentation or to schedule one-on-one meetings with the company, please send an email to [email protected]. The corporate website of Zura Bio Limited can be found at www.zurabio.com. Megan K. Weinshank serves as the Head of Corporate Affairs at Zura Bio Limited.
For the latest updates on the Jefferies Global Healthcare Conference 2025, you can check the conference's official website or Zura Bio's investor relations section on their website.
- The latest scientific updates on Zura Bio's medical-condition focused therapies and treatments, including their lead product candidate tibulizumab (ZB-106), may be found during their presentation at the Jefferies Global Healthcare Conference 2025.
- In addition to their lead product, Zura Bio's pipeline encompasses dual-pathway product candidates aimed at rectifying immune system imbalances, such as crebankitug (ZB-168) and torudokimab (ZB-880), both of which have completed Phase 1/1b studies.
- Amidst the backdrop of health-and-wellness discussions at the Jefferies Global Healthcare Conference 2025, cloud technology may assist in live streaming Zura Bio's presentation, ensuring wider access to news and updates on their clinical-stage immunology advancements.
